Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab with Decitabine and Chemotherapy in Metastatic Pancreatic Cancer
NCT06454448Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Jun 2024; status: recruiting.
02
Drugs
adebrelimab
Beyond the preview
Go deeper on NCT06454448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06454448.